Background and Objective: The purpose of our study was to explore the immediate and long-term effects of socially assistive robots (SARs) on neuropsychiatric symptoms (NPSs), behavioral and psychological symptoms of dementia (BPSD), positive emotional experiences, and social interaction in older people living with dementia. Methods: We set keywords and used Boolean operators to search the CINAHL, Cochrane Library, EMBASE, IEEE Digital Library, MEDLINE, PsycINFO, PubMed, Web of Science, Scopus, and Chinese Electronic Periodical Service from inception to February 2022 for randomized controlled trials. The Cochrane Collaboration bias assessment tool was used to assess article quality, and RevMan 5.4.1 software was used to conduct the meta-analysis. Results: A total of 14 studies were included in the meta-analysis. SARs can help people living with dementia reduce their NPS of depression and anxiety, provide happiness from positive emotional experiences, and improve their social interaction through conversation. However, there was no significant improvement in agitation behavior, overall BPSD, or quality of life in people living with dementia. In follow-up, it was found that the effect of SRT was limited. Conclusion: SARs can reduce depression and increase positive emotions in people living with dementia. They may also reduce the burden on healthcare workers during the COVID-19 pandemic. This research was registered on PROSPERO CRD42020169340.
Background: The optimum approach to enhance the understanding toward dementia is to experience how patients feel as they experience the manifestations of the disease. The application of virtual reality (VR) and relevant innovative technologies for developing caregiver training programs allows caregivers to better understand dementia and empathize with patients.Objectives: To develop a VR-based experiential training course on individualized care for the behavioral and psychological symptoms of dementia (BPSD).Methods: The participants were caregivers of patients with dementia. They assessed the usability of the VR product after the intervention and the VR experience as a preliminary measure of the effectiveness of the intervention using a usability scale and a self-reported appraisal scale, respectively.Results and Conclusion: Ten in-service and in-home caregivers completed the VR training course. The course yielded a usability score of 74.06 points, indicating excellent usability. The content validity index (CVI) of the self-reported VR experience appraisal scale ranged from 0.8-1, scale-level CVI was 0.81, and reliability (Cronbach's & alpha;) was 0.929. The mean score of the overall scale was 4.67 & PLUSMN; 0.33. These findings suggest that the VR-based experiential training course enabled the home caregivers to deepen their understanding of the BPSD shown by community-dwelling patients and, therefore, to provide better care services. The course developed in this study is the first VR course directed toward dementia care in Taiwan. Given its excellent usability, as well as the effectiveness of the VR experience appraisal scale for deepening the caregivers' skills in managing patients' BPSD symptoms, the course can be promoted and applied in caregiver training programs for dementia in the future.
We developed a multimedia e-learning platform by integrating a digital board game with narrative case studies to train long-term care staff. Twenty participants completed a single-group pretest–posttest evaluation using the Lesbian, Gay, Bisexual, Transgender Knowledge and Attitudes Scale, showing significant improvement (p < 0.001). System logs recorded 90% of the completed narrative prompts, with application programming interface response times averaging under 120 milliseconds, showing technical stability. The three-layer architecture: HyperText Markup Language 5/JavaScript front-end, Hypertext Preprocessor/representational state transfer application programming interface back-end, and My Structured Query Language database. The architecture enables real-time synchronization and modular scalability and ensures the platform’s adaptability, supporting gender-friendly education and offering a transferable professional training program aligned with sustainable development goals.
BACKGROUND The global COVID-19 pandemic has had negative impacts on people's health, causing physiological and psychological problems. The benefits of online mindfulness intervention (OMI) are known from existing studies. However, no comprehensive reviews and extensive meta-analyses of their effectiveness have been conducted. OBJECTIVE The primary purpose of this meta-analysis was to investigate the effects of OMI on physiological and psychological health in adults during the COVID-19 pandemic; the secondary aim was to perform subgroup analysis to determine which protocol could maximize the benefits. METHODS We electrically searched for randomized controlled trials published from January 2000 to June 2022 in the CEPS, CINAHL, Cochrane Library, PubMed/MEDLINE, and EMBASE. The PRISMA checklist was used. RESULTS We identified 20 studies for inclusion. OMI has a large effect on depression and anxiety; a medium effect on sleep problems and perceived stress; and a small effect on mindfulness. Subgroup analysis indicated that OMI was more effective on depression and anxiety in COVID-19 patients than in non-COVID-19 patients. The group approach of OMI was discovered to exert a greater effect on depression and the individual approach to be more effective on anxiety. By the GRADE approach, the quality of this evidence was deemed “moderate”, and the effect of the intervention is Favors. CONCLUSIONS Despite the heterogeneity of outcomes across studies, our study suggested that OMI can be a complementary and effective tool during an epidemic. Therefore, these interventions will be one of the important ways to overcome quarantine, maintain social distancing and maintain physical and mental health. CLINICALTRIAL This research was constructed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and registered on PROSPERO (CRD 42022320783)